Form 4: Travere Therapeutics Director Sandra Poole Reports Stock and Option Transactions

Director Sandra Poole reported acquiring shares and options in Travere Therapeutics under the company's equity incentive plan.

Summary

• Sandra Poole, a director of Travere Therapeutics, reported transactions involving the company's common stock and stock options.
• On May 8, 2024, Poole acquired 6,500 shares of common stock and 19,500 stock options.
• The stock acquisition was an automatic equity grant under the company's 2018 Equity Incentive Plan.
• Poole also disposed of 6,500 shares.
• The stock options have an exercise price of $6.82 and expire on May 7, 2034.
• The equity award vests over a one-year period.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The acquisition of shares and options could be seen as a positive, but the disposal of shares could be seen as a negative.

Positives

• The acquisition of stock and options by a director could be seen as a positive sign of confidence in the company's future.

Negatives

• The disposal of 6,500 shares could be seen as a negative sign.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are subject to regulatory scrutiny to prevent insider trading.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment.

Key Dates